IBEX:NASDAQIBEX Limited analysis

IBEX is trading at $30.92, comfortably above its near‑term support of $29.07 but still below the 200‑day SMA of $33.56, indicating a short‑term bounce within a longer‑term downtrend. The RSI of 52 and a bearish MACD histogram suggest neutral momentum with a slight downside bias, while the current price reflects a substantial discount to the DCF‑derived fair value of $59.26 and a PE multiple of 9.66 versus an industry average of 36.8. Revenue grew 17% YoY and EPS accelerated 22% in the latest quarter, underscoring strong top‑line momentum. Operating margins are approaching 10% and ROE stands at an impressive 33%, highlighting efficient capital use. The company announced a $20 million share‑repurchase program and a strategic AI partnership, reinforcing confidence in its growth narrative.
Despite a 30‑day volatility of over 54% and a max drawdown of 37%, the stock benefits from a low beta (≈0.94), a modest debt‑to‑equity ratio, and a solid free cash flow generation of $31.6 million. Analyst consensus remains a “hold” with a target price of $37.50, implying roughly 21% upside, while the market sentiment index signals “Extreme Greed,” suggesting heightened investor optimism.